Erythropoietin protects against diabetes through direct effects on pancreatic β cells

Diana Choi, Stephanie A. Schroer, Shun Yan Lu, Linyuan Wang, Xiaohong Wu, Yunfeng Liu, Yi Zhang, Herbert Y. Gaisano, Kay Uwe Wagner, Hong Wu, Ravi Retnakaran, Minna Woo

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

A common feature among all forms of diabetes mellitus is a functional β-cell mass insufficient to maintain euglycemia; therefore, the promotion of β-cell growth and survival is a fundamental goal for diabetes prevention and treatment. Evidence has suggested that erythropoietin (EPO) exerts cytoprotective effects on nonerythroid cells. However, the influence of EPO on pancreatic β cells and diabetes has not been evaluated to date. In this study, we report that recombinant human EPO treatment can protect against diabetes development in streptozotocin-induced and db/db mouse models of type 1 and type 2 diabetes, respectively. EPO exerts antiapoptotic, proliferative, antiinflammatory, and angiogenic effects within the islets. Using β-cell-specific EPO receptor and JAK2 knockout mice, we show that these effects of EPO result from direct biological effects on β cells and that JAK2 is an essential intracellular mediator. Thus, promotion of EPO signaling in β cells may be a novel therapeutic strategy for diabetes prevention and treatment.

Original languageEnglish (US)
Pages (from-to)2831-2842
Number of pages12
JournalJournal of Experimental Medicine
Volume207
Issue number13
DOIs
StatePublished - Dec 20 2010

Fingerprint

Erythropoietin
Erythropoietin Receptors
Streptozocin
Type 1 Diabetes Mellitus
Knockout Mice
Type 2 Diabetes Mellitus
Cell Survival
Diabetes Mellitus
Anti-Inflammatory Agents
Growth

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Choi, D., Schroer, S. A., Lu, S. Y., Wang, L., Wu, X., Liu, Y., ... Woo, M. (2010). Erythropoietin protects against diabetes through direct effects on pancreatic β cells. Journal of Experimental Medicine, 207(13), 2831-2842. https://doi.org/10.1084/jem.20100665

Erythropoietin protects against diabetes through direct effects on pancreatic β cells. / Choi, Diana; Schroer, Stephanie A.; Lu, Shun Yan; Wang, Linyuan; Wu, Xiaohong; Liu, Yunfeng; Zhang, Yi; Gaisano, Herbert Y.; Wagner, Kay Uwe; Wu, Hong; Retnakaran, Ravi; Woo, Minna.

In: Journal of Experimental Medicine, Vol. 207, No. 13, 20.12.2010, p. 2831-2842.

Research output: Contribution to journalArticle

Choi, D, Schroer, SA, Lu, SY, Wang, L, Wu, X, Liu, Y, Zhang, Y, Gaisano, HY, Wagner, KU, Wu, H, Retnakaran, R & Woo, M 2010, 'Erythropoietin protects against diabetes through direct effects on pancreatic β cells', Journal of Experimental Medicine, vol. 207, no. 13, pp. 2831-2842. https://doi.org/10.1084/jem.20100665
Choi, Diana ; Schroer, Stephanie A. ; Lu, Shun Yan ; Wang, Linyuan ; Wu, Xiaohong ; Liu, Yunfeng ; Zhang, Yi ; Gaisano, Herbert Y. ; Wagner, Kay Uwe ; Wu, Hong ; Retnakaran, Ravi ; Woo, Minna. / Erythropoietin protects against diabetes through direct effects on pancreatic β cells. In: Journal of Experimental Medicine. 2010 ; Vol. 207, No. 13. pp. 2831-2842.
@article{0bc62c5c7a424b4fba2b4da2b46ab93e,
title = "Erythropoietin protects against diabetes through direct effects on pancreatic β cells",
abstract = "A common feature among all forms of diabetes mellitus is a functional β-cell mass insufficient to maintain euglycemia; therefore, the promotion of β-cell growth and survival is a fundamental goal for diabetes prevention and treatment. Evidence has suggested that erythropoietin (EPO) exerts cytoprotective effects on nonerythroid cells. However, the influence of EPO on pancreatic β cells and diabetes has not been evaluated to date. In this study, we report that recombinant human EPO treatment can protect against diabetes development in streptozotocin-induced and db/db mouse models of type 1 and type 2 diabetes, respectively. EPO exerts antiapoptotic, proliferative, antiinflammatory, and angiogenic effects within the islets. Using β-cell-specific EPO receptor and JAK2 knockout mice, we show that these effects of EPO result from direct biological effects on β cells and that JAK2 is an essential intracellular mediator. Thus, promotion of EPO signaling in β cells may be a novel therapeutic strategy for diabetes prevention and treatment.",
author = "Diana Choi and Schroer, {Stephanie A.} and Lu, {Shun Yan} and Linyuan Wang and Xiaohong Wu and Yunfeng Liu and Yi Zhang and Gaisano, {Herbert Y.} and Wagner, {Kay Uwe} and Hong Wu and Ravi Retnakaran and Minna Woo",
year = "2010",
month = "12",
day = "20",
doi = "10.1084/jem.20100665",
language = "English (US)",
volume = "207",
pages = "2831--2842",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "13",

}

TY - JOUR

T1 - Erythropoietin protects against diabetes through direct effects on pancreatic β cells

AU - Choi, Diana

AU - Schroer, Stephanie A.

AU - Lu, Shun Yan

AU - Wang, Linyuan

AU - Wu, Xiaohong

AU - Liu, Yunfeng

AU - Zhang, Yi

AU - Gaisano, Herbert Y.

AU - Wagner, Kay Uwe

AU - Wu, Hong

AU - Retnakaran, Ravi

AU - Woo, Minna

PY - 2010/12/20

Y1 - 2010/12/20

N2 - A common feature among all forms of diabetes mellitus is a functional β-cell mass insufficient to maintain euglycemia; therefore, the promotion of β-cell growth and survival is a fundamental goal for diabetes prevention and treatment. Evidence has suggested that erythropoietin (EPO) exerts cytoprotective effects on nonerythroid cells. However, the influence of EPO on pancreatic β cells and diabetes has not been evaluated to date. In this study, we report that recombinant human EPO treatment can protect against diabetes development in streptozotocin-induced and db/db mouse models of type 1 and type 2 diabetes, respectively. EPO exerts antiapoptotic, proliferative, antiinflammatory, and angiogenic effects within the islets. Using β-cell-specific EPO receptor and JAK2 knockout mice, we show that these effects of EPO result from direct biological effects on β cells and that JAK2 is an essential intracellular mediator. Thus, promotion of EPO signaling in β cells may be a novel therapeutic strategy for diabetes prevention and treatment.

AB - A common feature among all forms of diabetes mellitus is a functional β-cell mass insufficient to maintain euglycemia; therefore, the promotion of β-cell growth and survival is a fundamental goal for diabetes prevention and treatment. Evidence has suggested that erythropoietin (EPO) exerts cytoprotective effects on nonerythroid cells. However, the influence of EPO on pancreatic β cells and diabetes has not been evaluated to date. In this study, we report that recombinant human EPO treatment can protect against diabetes development in streptozotocin-induced and db/db mouse models of type 1 and type 2 diabetes, respectively. EPO exerts antiapoptotic, proliferative, antiinflammatory, and angiogenic effects within the islets. Using β-cell-specific EPO receptor and JAK2 knockout mice, we show that these effects of EPO result from direct biological effects on β cells and that JAK2 is an essential intracellular mediator. Thus, promotion of EPO signaling in β cells may be a novel therapeutic strategy for diabetes prevention and treatment.

UR - http://www.scopus.com/inward/record.url?scp=78650397022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650397022&partnerID=8YFLogxK

U2 - 10.1084/jem.20100665

DO - 10.1084/jem.20100665

M3 - Article

C2 - 21149549

AN - SCOPUS:78650397022

VL - 207

SP - 2831

EP - 2842

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 13

ER -